The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
YESCARTA (Gilead Sciences Pty Ltd)
Product name
YESCARTA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
199 working days (255)
Active ingredients
T Cells - axicabtagene ciloleucel, cryopreserved - T - Yescarta
Registration type
Biologicals
Indication
Class 4 biological
YESCARTA is a genetically modified autologous immunocellular therapy for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.